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Classical dendritic cells (cDCs) form a critical interface between innate and adaptive immunity. As myeloid
immune cell sentinels, cDCs are specialized in the sensing of pathogen challenges and cancer. They translate
the latter for T cells into peptide form. Moreover, cDCs provide additional critical information on the original
antigen context to trigger a diverse spectrum of appropriate protective responses. Here we review recent
progress in our understanding of cDC subsets in mice. We will discuss cDC subset ontogeny and transcrip-
tion factor dependencies, as well as emerging functional specializations within the cDC compartment in
lymphoid and nonlymphoid tissues.Introduction
The vertebrate immune system evolved to react to infection and
injury caused by bacteria, fungi, viruses, and immunogenic
particles (collectively referred to here as antigens [Ags]) by
mounting protective immune responses that improve survival.
The highly diverse Ag receptor repertoire required for this broad
and almost unlimited reactivity is encoded by T and B lympho-
cytes. Due to the randomness of the somatic rearrangements
generating T and B cell receptors, the repertoire bears reactivity
to non-self Ags, as well as self-proteins. Consequently, mecha-
nisms must be in place to avoid fatal autoimmune reactions.
Burnet’s clonal selection theory proposed that Ag-specific lym-
phocytes are selected for self- or non-self Ags and undergo
clonal expansion upon exposure to the latter (Burnet, 1957).
However, early studies based on in vitro ‘‘Mishell-Dutton
cultures’’ already postulated accessory adherent, nonlymphoid
immune cells required for efficient lymphocyte activation (Hart-
mann et al., 1970), a notion later substantiated with the discovery
of MHC restriction of T cell stimulation (Zinkernagel and Doherty,
1974). Although these accessory cells were first thought to be
Metchninkoff’s macrophages, studies in the early seventies
identified among splenocytes so-called A or 3rd cells that pro-
moted adaptive in vitro immune responses (Cosenza et al.,
1971). About the same time, Ralph Steinman discovered in the
mouse spleen a rare population of cells characterized by stellate
morphology and extended veils (Steinman and Cohn, 1973). He
named them dendritic cells (DCs) after the Greek word for tree
(dendron), but their biological significance met considerable
skepticism. It took the persistence of Steinman and his col-
leagues to provide, over the following years, further compelling
evidence for the uniqueness of their novel cell type. In another
milestone study they demonstrated that DCs, which prominently
express both major histocompatibility complex class (MHC) I
and II molecules (Nussenzweig et al., 1980; Steinman et al.,
1979), were unrivaled stimulators of T cells in primary mixed leu-
kocytes reactions (MLR) (Steinman and Witmer, 1978). In addi-
tion, Steinman showed that DCs could process protein Ag and
initiate Ag-specific cellular immune responses (Nussenzweig
et al., 1980). For his pioneering work in establishing DC function
and biology, as well as his subsequent efforts toward the exploi-
tation of these cells for vaccination, Ralph Steinman was hon-
ored in 2011 with the Nobel Prize in Physiology or Medicine.642 Immunity 40, May 15, 2014 ª2014 Elsevier Inc.MHC-II-expressing non-B cells have been identified in almost
every tissue investigated, including the intestine, heart, and
kidney, with the notable exception of the brain parenchyma. All
DCs share the capability to efficiently uptake and process Ags
for presentation to naive T cells. However, in the decades since
Steinman’s seminal discovery, DC subsets have emerged that
considerably differ in ontogeny, localization, cytokine secretion
pattern, and immunological function. In this review we summa-
rize recent findings and scientific progress in our understanding
of murine DC subset development and function. For information
regarding human DC subsets, we refer the reader to other excel-
lent recent reviews (Haniffa et al., 2013; Villadangos and Short-
man, 2010). We will mainly, but not exclusively, focus on murine
classical DC (cDC) subsets, bywhichwemean all DCs other than
plasmacytoid DCs (pDCs) and monocyte-derived DCs (moDCs).
Unifying cDC Features: What Makes These Cells So
Special?
Before we discuss individual cDC subsets, we briefly recapitu-
late some of the unique and potentially unifying features of these
highly phagocytic sentinels that seem to have evolved to
constantly sense and respond to their immediate environment
and communicate with T cells.
Antigen Processing and Presentation
cDCs are specialized in Ag processing and can—probably
opposed to most other immune and nonimmune cells—effi-
ciently present endogenous and exogenous Ag in both MHC-I
and -II contexts. The unconventional presentation of exogenous
noncytosolic Ags on MHC-I by cDCs relies on ‘‘cross-presenta-
tion’’ (Bevan, 1976): a phenomenon critical for immunity against
viruses and intracellular bacteria (Rock, 2003). The detailed
machinery enabling the unique Ags’ transport from endosome
to cytosol is under intense investigation with different pathways
being discussed (Joffre et al., 2012). Unconventional presenta-
tion of endogenous cytosolic Ags on MHC-II by cDCs relies in
contrast on autophagy (Paludan et al., 2005). Accordingly, this
pathway is impaired in ATG5-deficient cDCs, although their Ag
cross-presentation remains intact (Lee et al., 2010). As opposed
to macrophages, cDCs degrade their engulfed cargo slowly and
can control lysosomal degradation potentially to preserve
peptides for T cell recognition (Savina et al., 2006). This activity
is influenced by the maturation status of the DC, with
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cation and Ag proteolysis (Trombetta et al., 2003). Toll-like
receptor (TLR) ligand exposure also stimulates Ag macro-pino-
cytosis, ensuring efficient MHC-peptide (MHCp) formation under
inflammatory conditions (West et al., 2004). Interestingly, the
glycolytic rate of DCs is also affected by TLR stimulation trig-
gering a circuit that ensures the de novo synthesis of fatty acids
critical for proper DC activation (Everts et al., 2014).
Migration
cDCs are strategically positioned at body barriers and also organ
entry ports, such as the splenic marginal zone. To ensure stimu-
lation of naive T cells, cDCs require efficient directional migration
toward T cell zones either within their respective lymphoid organ
of residence or toward remote tissue-draining lymph nodes
(LNs). Peripheral cDC migration via afferent lymphatics is
CCR7 dependent (Fo¨rster et al., 1999) and cDCs utilize CCL19
and CCL21, the same chemokine cues as migrating T cells
that enter the LN. Interestingly, mobilization of cDCs can involve,
in addition to the chemokine receptor switch, autocrine desensi-
tization by chemokine expression (Dieu et al., 1998). Immobilized
CCL21 on, or stored in, lymphatic endothelium plays a critical
role in facilitating chemotaxis and arrest of migrating tissue
DCs to enter the afferent lymphatics (Tal et al., 2011). Comple-
mentary roles in cDC migration have been suggested for other
chemokine receptors and S1P1/S1P3 signaling, but CCR7
seems to be the major player. Integrins, on the other hand, are
dispensable for themigration of cDCs to LNs under physiological
conditions (La¨mmermann et al., 2008) but are needed for optimal
migration during contact sensitization (Johnson et al., 2006).
Intratissue migration of lymphoid organ-resident cDCs, although
seemingly also CCR7 dependent, remains less well understood.
Recruitment of splenic CD11b+ cDCs to the bridging channels of
themarginal zone is controlled by the chemotactic receptor EBI1
(Gatto et al., 2013). A similar scenario was suggested for cDC
movement in the Peyer’s patch, i.e., the CCR6-CCL20 axis con-
trolling migration toward the mucosal surfaces, whereas the
CCR7-CCL19 axis is important for CD8+ DC localization to the
T cell region (Iwasaki and Kelsall, 2000). The highly specific
expression of the chemokine receptor XCR1 on cross-present-
ing DCs (Dorner et al., 2009) orchestrates their intratissue posi-
tioning in the thymus (Lei et al., 2011). The MHC-II-associated
invariant chain (CD74) also seems to be involved in the coordina-
tion of DC migration, because CD74-deficient DCs display
increased motility, whereas DCs overexpressing CD74 due to
absence of cathepsin S migrate at lower speed (Faure-Andre´
et al., 2008).
Specialization in T Cell Crosstalk
cDCs have unrivaled potential to stimulate T cells in an MLR
in vitro (Steinman and Witmer, 1978). Indeed, studies of mice
lacking cDCs, after their constitutive or conditionally ablation,
have confirmed the central role of cDCs in the initiation of naive
T cell responses (Birnberg et al., 2008; Jung et al., 2002) and the
effective restimulation of memory T cells. Importantly though,
T cell encounter of MHCp complexes on cDCs has, depending
on its context, distinct outcomes. Productive, protective T cell
responses, including proliferation, T helper (Th) cell polarization,
and memory formation, are believed to rely on three distinct
stimuli: cognate MHCp encounter, costimulatory signals pro-
vided by B7 family members, and instructing cytokines. All threesignals can be derived from DCs for productive T cell priming to
occur. Furthermore, these signals seem to have to come
from the same DC, because only pathogen-exposed DCs (not
inflammation or cytokine-stimulated DCs) can direct full Th cell
differentiation (Spo¨rri and Reis e Sousa, 2005). Direct recognition
of pathogen-associated Ag by DCs, therefore, seems critical for
the initiation of protective T cell responses, suggesting that
inflammatory mediators can amplify, but not initiate, adaptive
immunity. Such a scenario ensures that T cells read the original
context of the cognate Ag, for instance its association with
pathogen- or danger-associated molecular patterns. Indeed, it
has been proposed that DCs might even maintain the distinction
between innocuous Ags and the one received in TLR-ligand
context on the single-cell level by segregating their cargo (Blan-
der and Medzhitov, 2006), although this remains to be confirmed
in an in vivo setup.
T cell encounter of MHCp on DCs that lack costimulatory
molecules contributes to peripheral tolerance (Hawiger et al.,
2001; Probst et al., 2003). This notion is supported by the inti-
mate interaction of steady-state T cells and DCs under physio-
logical conditions (Scheinecker et al., 2002). Moreover, DCs
can also actively silence T cells by expressing molecules, such
as Programmed cell death 1 ligand 1 (PD-L1), which deliver
inhibitory signals (Carter et al., 2002). Further evidence for the
central role of DCs as critical ‘‘hubs’’ for T cell activation stems
from the fact that they are under constant control of thymic
and inducible T regulatory (Treg) cells. Relief of this ‘‘Treg cell
brake’’ is sufficient to unleash autoreactive cytotoxic T lympho-
cytes (CTLs) and cause autoimmunity (Feuerer et al., 2009).
Interestingly, removal of Treg cells and thus control of DCs
also reveals otherwise latent antitumor immunity, as it contrib-
utes to the clinical efficacy of costimulation blockades (Mara-
belle et al., 2013; Vom Berg et al., 2013). Of note, the crosstalk
between T cells and DCs is bidirectional; CD40L-expressing
T cells critically promote DC ‘‘maturation’’ (Elgueta et al.,
2009). Moreover, T cells, as well as innate immune cells, can
also shape the cDC compartment by production of the DC poie-
tin Fms-related tyrosine kinase 3 ligand (Flt3L) (Saito et al., 2013;
Guermonprez et al., 2013).
Classical DCs
cDCs can be divided into at least two main subsets character-
ized by either CD8a and CD103 or CD11b expression. Both sub-
populations can be found in lymphoid tissue, including spleen,
LN, and bone marrow (BM), as well as most nonlymphoid tissue.
CD8a+ and CD103+ cDCs
Heterogeneity within the DC population was first demonstrated
by both the Shortman and Steinman groups, including the dis-
covery of a CD8a-expressing DC subset in murine lymphoid
organs (Crowley et al., 1989; Vremec et al., 1992). An equivalent
population also exists in nonlymphoid tissues, although these
cells do not express CD8 but are instead identified by the
CD103 integrin marker (aEb7) (Bursch et al., 2007; del Rio
et al., 2007) (see below). CD8a+ and CD103+ cDCs are to date
the best-characterized cDC subset, both phenotypically and
by gene expression signature (Edelson et al., 2010), and they
also appear to be conserved through evolution (Crozat et al.,
2010). Indeed, transcriptome profiling allowed the alignment of
CD8a+ lymphoid organ and CD103+ nonlymphoid tissue cDCsImmunity 40, May 15, 2014 ª2014 Elsevier Inc. 643
Figure 1. Development of cDC Subsets and
Profiles of Key Transcription Factor Profiles
DCs arise from commonmonocyte-DCprecursors
(MDPs) in the BM, which differentiate into com-
mon monocyte progenitors (cMoPs) or common
DC precursors (CDPs). CDPs can give rise to
pDCs or pre-DCs that display considerable
heterogeneity. Zbtb46-expressing pre-DCs are
committed cDC precursors, which reach lymphoid
and nonlymphoid tissues via the circulation. The
heat map depicts the expression of selected key
DC transcription factors throughout the commit-
ment. Arrows within the heat map fields indicate
phenotype of transcription-factor-deficient mice
in different populations. The down arrow (Y) in-
dicates a reduction inmutantmice, up arrow ([) an
increase, and horizontal arrow (4) unchanged
numbers of the cells. Asterisk indicates reduced
expression of E2-2 may favor the conversion of
pDCs into CD8+CX3CR1
+ splenic DCs.
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equivalent of CD8a+ and CD103+ mouse DCs (Villadangos and
Shortman, 2010) and the identification of the chemokine recep-
tor XCR1 as a potential unifying marker of this DC subset in both
human andmice (Bachem et al., 2010; Crozat et al., 2010; Dorner
et al., 2009).
Splenic CD8a+ cDCs are functionally specialized in cross-
presenting exogenous Ags on MHC-I molecules to CD8+
T cells (den Haan et al., 2000). Of note, the entry of exogenous
protein to the cytosol also renders these cells uniquely sensitive
to ablation by an extracellular cytochrome c (CytC) challenge (Lin
et al., 2008). Cross-presentation activity has also been shown for
skin-derived CD103+ cDCs (Bedoui et al., 2009). CD8a+ cDCs
furthermore present glycolipid Ags in CD1d context and can acti-
vate and polarize iNKT toward the production of T helper 1 (Th1)
or Th2 cytokines (Arora et al., 2014). Specifically, discrete glyco-
lipid Ag structures were reported to modulate expression of cos-
timulatory and coinhibitory molecules and to thereby influence
the antigen-presenting cell (APC) potential of CD8a+ cDCs (Arora
et al., 2014). Stimulation of TLR signaling on the CD8a+ and
CD103+ cDC lineage induces prominent secretion of ‘‘bioactive’’
IL12p70 (Reis e Sousa et al., 1997). It is noteworthy that, in
contrast to macrophages, secretion of IL-12 production by
CD8a+ cDCs requires c-Rel (Grumont et al., 2001).
Development of CD8a+ cDCs and their nonlymphoid tissue
equivalent, the CD103+ (CD11b) cDCs, is orchestrated by the
same transcription factors: inhibitor of DNA binding 2 (Id2), inter-
feron regulatory factor 8 (IRF8), basic leucine zipper ATF-like 3
transcription factor (BATF3), and the nuclear factor interleukin
3 regulated (NFIL3). Deletion of either of these genes leads to a
severe developmental defect of CD8a+ DCs, as well as
CD103+ nonlymphoid tissue cDCs, but not CD11b+ cDCs
(Figure 1; Aliberti et al., 2003; Ginhoux et al., 2009; Hacker644 Immunity 40, May 15, 2014 ª2014 Elsevier Inc.et al., 2003; Hildner et al., 2008; Kashi-
wada et al., 2011). The hierarchy and
sequential involvement of these specific
transcription factors within the CD8a
and CD103 cDC lineage is emerging
(Murphy, 2013). IRF8 is obligatory for
the development of Id2-expressing DCprecursors and BATF3 is induced at later maturation stages of
CD8a and CD103 cDCs (Hildner et al., 2008). Indeed, CD8a+
cDC development can be observed in BATF3-deficient mice in-
fected with intracellular pathogens or treated with IL-12, a
bypass mediated through compensatory BATF and BATF2
expression (Tussiwand et al., 2012). Furthermore, short-term
development of CD8a and CD103 cDCs has been observed in
the absence of Id2, NFIL3, and BATF3 expression, which collec-
tively suggests that IRF8 is the master regulator of CD8a and
CD103 cDC lineage development (Seillet et al., 2013). In addition
to its regulation of development, IRF8 was recently shown to
regulate expression of the transcription factor L-MYC, which
controls mature CD8a+ DC proliferation and functionality (KC
et al., 2014).
CD11b+ cDCs
CD11b+ cDCs are the most abundant cDCs in lymphoid organs
except for the thymus and can also be found in nonlymphoid
tissue. In contrast to CD8a and CD103 DCs, the population
currently defined as CD11b+ cDCs is heterogeneous and
remains less well characterized. CD11b+ cDCs can, for instance,
be further segregated according to additional surface markers,
such as CD4 and the Endothelial cell-selective adhesion mole-
cule (ESAM) (Lewis et al., 2011); however, this subdivision does
not yield homogeneous populations, as indicated by massive
parallel single-cell transcriptome analysis (Jaitin et al., 2014).
Transcription factors that control general CD11b+ cDC devel-
opment include RelB (Wu et al., 1998), NOTCH2 (Lewis et al.,
2011), RBP-J (Caton et al., 2007), IRF2 (Ichikawa et al., 2004),
and IRF4 (Suzuki et al., 2004). Of note, IRF4 also controls func-
tional aspects of CD11b+ DCs, such as their MHC presentation
(Vander Lugt et al., 2014) and migration (Bajan˜a et al., 2012;
Gao et al., 2013). The significance of IRF4 for the CD11b+ cDC
development is still under debate (Murphy, 2013). However,
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deficiencies of IRF4 and NOTCH2 only partially impair this
compartment and have differential penetrance in distinct tissues
(Bajan˜a et al., 2012; Lewis et al., 2011). Moreover, in contrast to
CD8 and CD103+ cDCs, the hierarchy of transcription factor
required for CD11b+ cDC development is unknown and the pro-
nounced heterogeneity of this compartment considerably com-
plicates the interpretation of existing data.
When compared to CD8a+ DCs or pDCs, CD11b+ cDCs do
show a unifying signature (Robbins et al., 2008; Bar-On et al.,
2010). Interestingly, comparative transcriptional profiling
revealed that CD4EsamloCD11b+ cDCs, but not CD4+
EsamhiCD11b+ cDCs, harbor a monocytic signature including
expression of cytokine (Csf1r, Csf3r) and chemokine (Ccr2) re-
ceptors, as well as lysozyme (Lewis et al., 2011). Yet,
CD4Esamlo cDCs do not seem to derive from monocytes
(Lewis et al., 2011). This finding further highlights the hetero-
geneity of the CD11b+ cDC compartment, whose in-depth
understanding will probably require novel approaches unbiased
by historically defined surfacemarkers, including the definition of
the epigenomic landscape of cDCs, single-cell transcriptome
analysis, and the further elucidation of DC origins by fate map-
ping.
Given their heterogeneity, it is not surprising that the assign-
ment of specific functions to CD11b+ DCs has remained chal-
lenging. In fact, at least in lymphoid organs, CD11b+ DCs are still
mostly defined by the absence of activities associated with
CD8a+ DCs. This includes their inefficiency to cross-present
and produce specific cytokines, such as IL-12. It has however
been noted that CD11b+ cDCs are, as compared to CD8a+
cDCs, superior in the induction of CD4+ T cell immunity, poten-
tially because of their prominent expression of MHC-II presenta-
tion machinery (Dudziak et al., 2007; Lewis et al., 2011). This
specialization of CD11b+ cDCs was recently attributed to their
expression of the transcription factor IRF4 (Vander Lugt et al.,
2014). CD11b+ DCs can also be characterized by their produc-
tion of cytokines, such as IL-6 (Persson et al., 2013) and IL-23
(Schlitzer et al., 2013). Furthermore, splenic CD11b+ cDCs
were shown to be prominent producers of proinflammatory che-
mokines after TLR ligand exposure, such as CCL3, CCL4, and
CCL5 (Proietto et al., 2004). However, the in vivo relevance of
these activities remains unclear.
Nonclassical DCs
Monocyte-Derived DCs
As a consequence of inflammation or infection, lymphoid and
nonlymphoid organs can harbor DCs that originate from
monocyte infiltrates (Serbina et al., 2003) and have been termed
‘‘monocyte-derived DCs’’ (moDCs) or ‘‘inflammatory DCs’’
(iDCs) (Mildner et al., 2013; Segura and Amigorena, 2013).
moDCs are phenotypically difficult to discern from cDCs
because they share similar expression patterns of MHC-II,
CD11b, and CD11c; however, indicative of their monocytic
past, moDCs express CD64, the Fc-gamma receptor 1 (FcgRI)
(Plantinga et al., 2013; Tamoutounour et al., 2012). Monocytes
have long been known to give rise to DC-like cells that can
efficiently stimulate T cells when cultured in vitro in the presence
of Csf2 (GM-CSF) and IL-4 (Sallusto and Lanzavecchia, 1994). In
fact, it was the study of these BM culture-derived nonclassicalDCs that yielded many of our insights into DC biology. Gene
expression profiles of cDCs and BM culture-derived DCs, how-
ever, differ considerably (Xu et al., 2007). Earlier findings should
probably be revisited using either ex vivo isolates or cDC equiv-
alents generated in cultures driven by the growth factor Flt3L
(Naik et al., 2005) to draw conclusions on cDC biology. A relation
of moDCs and cDCs is supported by the fact that BM culture-
derived moDCs express the transcription factor zbtb46 (Satpa-
thy et al., 2012) that is restricted to cDCs in the immune system
(Meredith et al., 2012b). It also remains to be determined how
much BM culture-derived DCs reflect moDCs, i.e., their likely
in vivo equivalent, which itself remains insufficiently defined.
‘‘TNF-a and iNOS-producing DCs’’ (or TIP DCs) that appear
during pathogen-associated inflammation (Serbina et al., 2003)
have been considered the prototypic moDCs. However, given
the pronounced proinflammatory signature of these cells and
their Csf2-independent development (Greter et al., 2012), they
might represent activated effector monocytes rather than cDC-
like cells (Mildner et al., 2013). Another population suggested
to represent in vivo moDCs are DC-SIGN (CD209a)-positive
DCs that appear in LNs after TLR ligand challenge (Cheong
et al., 2010). Because these cells are Flt3L dependent and
express zbtb46, they can also be interpreted as activated
cDCs (Meredith et al., 2012a). Taken together, the definition of
moDCs clearly requires further study. Moreover, because
moDCs are most closely related to CD11b+ DCs, these efforts
will probably contribute to our understanding of the hetero-
geneous CD11b+ cDC compartment.
Plasmacytoid DCs
pDCs are found circulating in the blood and in peripheral organs
and display a characteristic surface phenotype andmorphology,
including a highly developed secretory compartment (Reizis
et al., 2011). Identified first in humans (Siegal et al., 1999) and
later in mice (Asselin-Paturel et al., 2001), pDCs harbor rear-
rangements of their IgH loci (Corcoran et al., 2003) and can, in
transfer experiments, arise from common lymphoid progenitors
(CLPs) (Manz et al., 2001). pDCs were therefore thought to be
related to the lymphoid lineage. However, pDCs clearly share
cDC characteristics, such as their strict Flt3L dependence for
development (Kingston et al., 2009), a restricted potential to
prime T cells, at least after activation (Sapoznikov et al., 2007),
and their overlapping though distinct transcription profile
(Robbins et al., 2008). pDCs are, however, best characterized
by their unique functional property to rapidly produce large
amounts of type I interferons upon viral infections (Nakano
et al., 2001; Siegal et al., 1999), a direct consequence of their
constitutive IRF7 expression (Honda et al., 2005). pDC develop-
ment and homeostasis are regulated by the helix-loop-helix tran-
scription factor E2-2 (also known as TCF4) (Cisse et al., 2008)
that facilitates pDC development by directly suppressing
expression of Id2 (Ghosh et al., 2010), a transcription factor crit-
ical for cDC development (Kusunoki et al., 2003). Conversely,
early deletion of E2-2 leads to a complete absence of pDCs
both in human and mouse (Cisse et al., 2008; Nagasawa et al.,
2008), and excision of the E2-2 gene in mature pDCs initiates
an alternative cDC transcription program including the expres-
sion of CD8a (Ghosh et al., 2010). These ‘‘converted’’ CD8a+
pDCs bear D-J rearrangement indicative of their pDC past and
can be discriminated from CD8a+ cDCs by their expression ofImmunity 40, May 15, 2014 ª2014 Elsevier Inc. 645
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et al., 2010). It remains to be shown whether and how these
‘‘ex-pDCs’’ contribute to immunity.
Langerhans Cells
LCs are a unique population of mononuclear phagocytes
restricted to the epidermal skin layer. Identified in the 19th
century, these cells gained special attention after the discovery
of the splenic DC. LCs express MHC-II and could stimulate an
MLR after in vitro culture with T cells. Moreover, it was the study
of LCs that led to the realization of distinct functional DC ‘‘matu-
ration’’ stages (Schuler and Steinman, 1985). LCs were long
considered prototype sentinel tissue-resident DCs sampling
their environment and migrating to skin-draining LNs to activate
naive T cells (Romani et al., 1989). However, no firm evidence for
a role of LCs in the priming of protective naive T cell immunity
could be established (Romani et al., 2012). Additionally, the
notion that LCs belong to the DC family has been confounded
by their distinct gene expression that is similar to that of macro-
phages, rather than cDCs (Miller et al., 2012). Notably, LCs also
share a prenatal origin withmost tissuemacrophages, which is in
stark contrast to the short-lived cDC compartment relying on
constant renewal by HSC-derived cells (see below). The LC
compartment is established before birth from fetal liver-derived
monocytes (Hoeffel et al., 2012), and LCs self-renew under
physiological steady-state conditions without replacement by
blood-borne precursors (Merad et al., 2002). In addition and in
contrast to cDCs, LC development is independent of Flt3L
(Ginhoux et al., 2009) but requires Csf1r receptor engagement
(Ginhoux et al., 2006), though not by Csf1, but rather its alterna-
tive ligand IL-34 (Wang et al., 2012). Collectively, these data
suggest that LCs are closer related to tissue-resident macro-
phages than to cDCs.
cDC Development
cDCs generally display a short half-life of approximately 3–
6 days and are constantly replenished from BM precursors in a
strictly Flt3L-dependent manner (McKenna et al., 2000). The
transcription factor PU.1 (Anderson et al., 2000), Gfi1 (Rathinam
et al., 2005), andCbfb (Satpathy et al., 2014) control the develop-
ment of the common DC lineage and absence of either of these
regulators leads to perturbed cDC development (Figure 1).
Myeloid and lymphoid branches of the immune system
bifurcate early in hematopoiesis into common myeloid and
lymphoid precursors (CMPs, CLPs) (Akashi et al., 2000; Kondo
et al., 1997). Early adoptive CMP and CLP transfer experiments
established that both cells have the potential to give rise to
cDCs, but concluded that most steady-state cDCs, including
CD8a-positive and -negative subsets, are of myeloid origin,
because CMPs vastly outnumber CLPs (Manz et al., 2001). DCs
thus initially share their origin with monocytes. Eventually, how-
ever, monocyte and DC committed precursors (MDPs) (Fogg
et al., 2006) either give rise to ‘‘common monocyte progenitors’’
(cMoPs) restricted to monocytes and their descendants (Het-
tinger et al., 2013) or commit toward a pDC or cDC fate (Figure 1;
Naik et al., 2006; Onai et al., 2007). A clonogenic CDP-derived
pre-DC population was first identified in lymphoid tissues (Diao
et al., 2006; Naik et al., 2006), subsequently found in the blood,
and shown to populate lymphoid organs via the circulation to
give rise to cDCs in lymphoid and nonlymphoid tissues (Liu646 Immunity 40, May 15, 2014 ª2014 Elsevier Inc.et al., 2009; Varol et al., 2009; Bogunovic et al., 2009). Although
these early studies suggested that pre-DCs can give rise to all
cDCs (Liu et al., 2009), detailed studies on the potential of
CDPs and pre-DCs in terms of their differential or preferential
development into either CD8a+ and CD103+ or into CD11b+
cDC subsets in lymphoid and nonlymphoid tissues are missing.
In the periphery, for instance, pre-DCs seem biased toward a
CD103+ cDC fate, whereas the origin of CD11b+ cDCs is hetero-
geneous (Ginhoux et al., 2009). In support of this notion, IRF8-
deficient mice lack CD8a+ and CD103+ lymphoid and nonlym-
phoid tissue cDCs (Aliberti et al., 2003) in accordance with the
strong reduction of CDPs (Scho¨nheit et al., 2013) and pre-DCs
(data not shown). These animals, however, do harbor CD11b+
cDCs (Aliberti et al., 2003). Precursors of CD11b+ cDCs might
thus bypass an IRF8-dependent pre-DC stage or pre-DCs could
themselves be heterogeneous. Pre-DCs of zbtb46-GFP reporter
animals can indeed be subdivided according to expression of the
lectin Siglec-H and zbtb46 (Satpathy et al., 2012). Of note, in
these studies only zbtb46-GFP-expressing pre-DCs gave rise
to MHC-II+ cDCs in culture, and therefore truly represent
committed pre-DCs (Figure 1). The exact potential of these
different pre-DC subsets to develop in vivo into the main
lymphoid and nonlymphoid tissue cDCpopulations needs further
investigation. Additional insight might come from DC fate map-
ping studies, such as the one exploiting DNGR-1 expression
(Schraml et al., 2013). It remains to be shown how well the
short-lived DC compartment is amenable to the Cre-loxP-based
approach. In addition, gene expression patterns of cDCs overlap
considerablywith that ofmacrophages andmonocytes, in partic-
ular after activation of the latter, which can seriously confound
such strategies.
Contributions of cDC Subsets in Lymphoid Organs
cDCs reside in tissues where they contribute functions that
can, but must not necessarily, be related to their generic, well-
accepted function as migratory APCs that mediate T cell
cross-talk. Below we will discuss the current knowledge of
cDCs that reside in lymphoid and selected nonlymphoid tissues.
Spleen
The spleen harbors at least three populations of resident cDCs:
CD8a+ cDCs, EsamhiCD11b+ cDCs, and EsamloCD11b+ cDCs.
CD8a+ cDCs represent about 20%–30% of the total splenic
DC compartment and are localized in the marginal zone where
they sample lymph- and blood-borne Ags and pathogens
(Idoyaga et al., 2009). Indeed, during infection, a fraction of sys-
temic, Gram-positive bacteria can associate in the blood with
platelets via the covalent opsonizing complement factor C3
and platelet receptor GPIb. These platelet-coated bacteria can
thereby be specifically targeted to splenic CD8a+ DCs in order
to allow protective immunity and avoid clearance by less immu-
nogenic macrophages (Verschoor et al., 2011). However, this
mechanism also renders CD8a+ cDCs a unique splenic entry
portal for intracellular pathogens, such as Listeria monocyto-
genes (Neuenhahn et al., 2006). CD8a+ cDCs furthermore effi-
ciently uptake apoptotic or necrotic cells from peripheral blood
(Iyoda et al., 2002) and are thus able to present exogenous tu-
mor- or virus-derived Ags. Depending on the context, Ag uptake
can result in cross-tolerance or cross-priming that is required for
the triggering of CTL responses to viral or cancer Ag in the
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Accordingly, BATF3-deficient mice, which specifically lack
CD8a+ cDCs, display for instance impaired West Nile Virus-spe-
cific CTL responses and ineffective tumor rejection (Hildner
et al., 2008). Further functional properties of splenic CD8a+
cDCs are their highly specific expression of the double-stranded
RNA sensor TLR3 (Edelson et al., 2010) and the T. gondii sensor
TLR11 (Koblansky et al., 2013) that combined with their predis-
position to secrete IL-12 critically contributes to the early anti-
parasite defense (Mashayekhi et al., 2011).
The splenic EsamhiCD11b+ cDC compartment shows a sub-
stantial overlap with CD4+ cDCs and represents 50%–60% of
the majority of splenic cDCs. Absence of this cell population,
as a result of an impairment of the Notch-signaling pathway by
CD11c-Cre-mediated DC-specific deletion of RBP/J (Caton
et al., 2007) or NOTCH2 itself (Lewis et al., 2011; Satpathy
et al., 2013), severely and specifically impairs CD4+ T cell
responses (Lewis et al., 2011). Like CD8a+ cDCs, CD11b+
cDCs are also located in the marginal zone and concentrate in
the bridging channels (Dudziak et al., 2007). Recruitment of
CD11b+ cDCs to this microanatomical niche is mediated by
the chemokine receptor EBI2 (Gatto et al., 2013) and might pro-
vide themwith critical growth or differentiation factors, such as B
cell-derived lymphotoxin (Kabashima et al., 2005). Esamhi cDCs
are poor producers of proinflammatory cytokines (Lewis et al.,
2011). Of note, the identity of Esamhi cDCs seems at least
partially controlled by the transcription factor Runx3, because
a DC-restricted Runx3 loss reduces their CD4+ T cell priming
capacity and shifts their gene expression signature toward
Esamlo cDCs (Dicken et al., 2013). Interestingly, Runx3-bound
genes are cobound by zbtb46, suggesting cooperation of these
transcription factors in the repression of the alternative Esamlo
cell fate (Dicken et al., 2013).
EsamloCD11b+ cDCs, the third spleen-resident cDC subset,
were most recently characterized (Lewis et al., 2011) and are
probably overlapping with cells previously termed CD8aCD4
‘‘double negative’’ (DN) cDCs (Vremec et al., 2000). These cells
can be identified by their expression of DCAL2 (also known as
Clec12a), which is expressed in 33D1CD8a+ splenic cDCs
but not in EsamhiCD11b+ cells (Lewis et al., 2011; Kasahara
and Clark, 2012). In line with their ‘‘monocytic’’ gene expression
signature, Esamlo cDCs are superior producers of inflammatory
cytokines upon TLR trigger (Kasahara and Clark, 2012; Lewis
et al., 2011) and efficient Th1 cell inducers in response to in vivo
CpG exposure (Kasahara andClark, 2012). The distinct functions
of Esamlo and Esamhi cDCs might suggest a labor division within
the CD11b+ cDC compartment with cytokine-producing Esamlo
cells representing ‘‘detectors,’’ which may supply Esamhi ‘‘pre-
senter’’ cells with defined cytokine micro-milieus at the recogni-
tion site (Lewis and Reizis, 2012).
Lymph Node
Like splenic cDCs, LN cDCs can be subdivided into CD8a and
CD8a+ subsets (Henri et al., 2001), but harbor in addition migra-
tory DCs that entered via the afferent lymphatics fromassociated
nonlymphoid tissues. The latter probably import insult-associ-
ated Ags for T cell stimulation (Ruedl et al., 2000), although their
exact role versus LN-resident cDCs remains to be determined.
LN-resident cDCs could serve to trigger T cell responses by
cross-presentation of the immigratingmonocytes alongside theircargo (Samstein et al., 2013). Cross-presentation by LN-resident
CD8a+ cDCs is, for instance, critical for responses to Ags
imported by LCs that themselves seem incompetent to prime
(Allan et al., 2003). However, it is less obvious in the case of
bona fide cDC immigrants, which are themselves considered
fully capable to prime T cells. Specific Ag transfer from moDCs
to resident cDCs for naive CD4+ T priming was also observed
in yeast-infected animals (Ersland et al., 2010). Thus, cell-to-
cell Ag transfer might be a more common theme to be explored
in the future. Interestingly, LN-resident, but not migratory, cDCs
have also been reported to sample follicular dendritic cell (FDC)-
retained Ags (McCloskey et al., 2011). LN-resident cDCs might
be important to maintain peripheral tolerance; however, recent
experiments suggest that at least under certain conditions,
migratory DCs are superior in this respect (Idoyaga et al.,
2013). Surprisingly, LN-resident cDCs also seem to control LN
entry of lymphocytes by modulating the maturation state of
high endothelial venules (Moussion and Girard, 2011), which
suggests cDC interactions with stromal components, an area
that clearly needs further exploration.
Thymus
In contrast to spleen or LN, thymic DCs are composed of a main
CD8a+ and a minor CD8a CD172a+ (SIRPa) cDC subset (Wu
and Shortman, 2005). Residing in the thymic medulla, these cells
were originally thought to mediate negative T cell selection
(Ardavı´n, 1997). However, the prime role in this process is played
by the medullary thymic epithelial cells (MTECs) (Yano et al.,
2008), which are in addition uniquely specialized to express a
vast array of otherwise periphery-restricted tissue antigens
(PTA), in part in an Aire-dependent manner (Anderson et al.,
2002). Accordingly, constitutive cDC ablation does not result in
an overt breakdown of central tolerance (Birnberg et al., 2008),
although thymic DCs might still be required for efficient presen-
tation of particular Ag, including the cross-presentation of
MTEC-derived PTA. Interestingly, and in contrast to splenic
CD8+ cDCs, thymic CD8+ cDCs harbor frequent D-J rearrange-
ments, suggesting that most of these cells derive in steady state
from intrathymic lymphoid precursors (Ardavı´n et al., 1993; Cor-
coran et al., 2003). The latter can be found within the DN1(c)
thymocyte gate characterized as CD4 or CD8lo CD117+
CD44+CD25+ cells (Luche et al., 2011). However, adoptively
transferred CMPs have also been shown to give rise to thymic
CD8a+ cDCs (Manz et al., 2001) and therefore these cells may
be of mixed origin. Thymic CD8a+ cDCs can cross-present
Ags to T cells in the absence of licensing factors (Dresch et al.,
2011) and these XCR1+ cells seem efficiently attracted to the
medulla by MTEC-derived XCL1 (Lei et al., 2011). Thymic
CD8a cDCs were suggested to immigrate at least in part from
the blood (Li et al., 2009), localizing to the thymic cortex and peri-
vascular regions, where they might sample blood-borne anti-
gens (Baba et al., 2009). Thymic CD8a cDCs cannot cross-pre-
sent (Proietto et al., 2008). In experimental settings, adoptively
transferred splenic cDCs were shown to contribute to negative
selection by carrying peripheral Ags in a tolerogenic context (Bo-
nasio et al., 2006). At least in the mouse, however, cDCs have
limited access to the circulation and these cells do not leave
the LN via efferent lymphatics. Interestingly, the migration of pe-
ripheral DCs to the thymus seems to depend on CCR2 (Baba
et al., 2009), which suggests a contribution ofmoDCs.Moreover,Immunity 40, May 15, 2014 ª2014 Elsevier Inc. 647
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Figure 2. Surface Phenotype of DCs
cDCs in lymphoid and nonlymphoid tissue differentiate from a circulating pre-DC. Within the tissue, the different cDC subsets can be divided according to the
indicated cell surface markers.
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into the thymus (Hadeiba et al., 2012), although the physiological
relevance of these pathways remains to be shown.
Bone Marrow
The BM hosts cDCs (Feuerer et al., 2003), which via intravital
microscopy have been shown to be organized into discrete
perivascular clusters (Sapoznikov et al., 2008). These cells are
distinct from moDCs (Milo et al., 2013) and share activities and
surface signatures with splenic cDCs (Sapoznikov et al., 2008)
but have not been dissected into subsets. Moreover, attempts
to assign to these cells a role as primary APCs for the stimulation
of naive T cells in the BM niches have failed and instead revealed
promiscuity—at least with respect to CTL responses (Milo et al.,
2013). In an interesting twist, these BM-resident cDCs were
found to constitute a critical survival niche for recirculating B
cells by providing macrophage migration inhibitory factor (Mif)
(Sapoznikov et al., 2008). This is reminiscent of the dependence
of marginal zone B cells on moDCs for survival and differentia-
tion, although the latter involves the TNF ‘‘superfamily’’ members
BAFF and APRIL (Bala´zs et al., 2002). Finally, the BM recently
emerged as a reservoir of long-lived CD4+ and CD8+ memory
T cells (Tokoyoda et al., 2009). However, whether cDCs are
involved in reactivation of the latter, or whether this is accom-
plished by the arguably more mobile, and after activation prob-
ably more potent, B cells (Lanzavecchia, 1987) remains to be
shown.
Contributions of cDC Subsets in Nonlymphoid Organs
Like lymphoid organs, most nonlymphoid tissues contain at least
two major subsets of cDCs that often share the aE integrin
CD103 marker but can be distinguished according to CD11b
expression (Figure 2). The study of nonlymphoid tissue DCs so
far largely involved tissues that are in contact with body surfaces,
such as the skin, lung, and intestine, and we will hence focus
on these organs. Of note, cDCs in these tissues are found
embedded in a network of tissue-resident macrophages and
additional moDCs (Tamoutounour et al., 2013; Varol et al.,
2009). Recruitment of the latter might be related to a constant
exposure of these sites to bacterial products that create a low-
grade inflammatory milieu and state of ‘‘primed homeostasis’’
(Zigmond et al., 2012). Steady-state presence of moDCs, which
are barely distinguishable from CD11b+ cDCs, probably compli-648 Immunity 40, May 15, 2014 ª2014 Elsevier Inc.cates the interpretation of the available data. However, recently,
additional markers were identified (such as CD64, CD24, and
MAR-1) that should allow in the near future better separations
of tissue-resident CD11b+ cDCs from moDCs.
Skin
LCs residing in the skin epidermis were long considered the prin-
cipal skin DC population and to be critical for the defense against
external threats. Indeed, LCs efficiently phagocytose pathogens
after epidermal cell injury and switch their chemokine expression
pattern from CCR6 to CCR7, i.e., from a ‘‘sessile’’ to a ‘‘mobile’’
mode (Dieu et al., 1998), allowing them to emigrate toward cuta-
neous LNs (Stoitzner et al., 2003). However, whether LCs them-
selves can stimulate naive T cells or require cross-presenting
LN-resident CD8a+ cDCs is under debate (Mayerova et al.,
2004; Allan et al., 2003). More recently, research has focused
on the DC compartment of the skin connective tissue layer, the
dermis, which was found to host multiple cDC subsets, as well
as moDCs. Analysis of reporter mice for langerin (CD207), a
C-type lectin required for characteristic LC Birbeck granules
(Kissenpfennig et al., 2005), revealed the existence of langerin-
expressing dermal DCs (Bursch et al., 2007; Ginhoux et al.,
2007). In addition to LC ‘‘in transit,’’ the dermis is currently
believed to comprise four cDC populations: CD103+CD207+
and CD103CD207+ cDCs, CD207CD11b+ cDCs, and cDCs
negative for CD207, CD11b, and CD103 (Henri et al., 2010).
The exact relationship of these subsets remains unknown and
mainly functions of CD103+CD11b cDCs and CD207CD11b+
cDCs have been addressed. Of note, the latter can also include
monocyte descendants, which show partial overlap in function
and gene expression with skin CD11b+ cDCs (Tamoutounour
et al., 2013). All dermal DC populations display CCR7-depen-
dent migration to cutaneous LNs (Henri et al., 2010; Ohl et al.,
2004) and all dermal cDC subsets can efficiently present Ags in
a MHC-II context (Bedoui et al., 2009).
Mirroring splenic cDC labor division, dermal cDCs display
functional specification. Thus, only CD207+CD103+ dermal
cDCs efficiently cross-present auto-Ag in a transgenic animal
model in which keratinocytes express a membrane form of
ovalbumin as a model antigen (Henri et al., 2010). Moreover, in
HSV-1-infected mice, only CD103+ dermal cells could present
viral Ag to naive CD8+ T cells (Bedoui et al., 2009). This estab-
lishes dermal CD103+ cDCs as the functional equivalent of
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CD103+ cDCs accordingly depends on IRF8, ID2, and BATF3
(Ginhoux et al., 2009; Hildner et al., 2008).
Interestingly, migratory dermal cDCs rather than LN-resident
cDCs seem critical for peripheral tolerance induction (Idoyaga
et al., 2013; Tamoutounour et al., 2013). Induction of Treg cells
needs retinoic acid (RA) (Coombes et al., 2007), produced by
the enzyme retinaldehyde dehydrogenase (RALDH). Among
dermal cDCs, RALDH activity is restricted to CD103CD11b+
cells (Guilliams et al., 2010), suggesting that this population is
specialized in raising Treg cell control to dampen immune
responses. In contrast to splenic EsamhiCD11b+ cDCs and intes-
tinal CD11b+ DCs (see below), dermal CD11b+ cDCs do not rely
on the transcription factor NOTCH2 for their generation (Lewis
et al., 2011). Additionally, a population of CD301b+ dermal
DCs, which are superior inducers of Th2 cell immune responses,
express CD11b (Kumamoto et al., 2013). LN-directed migration
of these cells, though not their generation, depends on IRF4 (Gao
et al., 2013).
Intestine
The intestine harbors a complex system of organized lymphoid
tissues as primary sites for the induction of adaptive mucosal
immune responses, including ileal Peyer’s patches, colonic
isolated lymphoid follicles, and more remote mesenteric lymph
nodes (MLNs). cDCs are in addition found in the lamina propria,
the mucosal immune effector site, alongside a prominent popu-
lation of monocyte-derived macrophages (Zigmond and Jung,
2013). Like other tissue cDCs, intestinal nonlymphoid organ
cDCs are Flt3L dependent and pre-DC derived (Bogunovic
et al., 2009). They are phenotypically defined by expression of
the integrins CD11c, CD103, and more recently CD24 (Schlitzer
et al., 2013) and can be further subdivided according to CD11b
expression. All intestinal cDCs are migratory cells and found,
for instance, in thoracic duct lymph after mesenteric lymphade-
nectomy (Cerovic et al., 2013). Of note, CD11b+ and CD11b
CD103+ DCs show distinct prevalence in proximal and distal
sections of the gut, suggesting functional specialization (Den-
ning et al., 2011). Most of the available data, however, are on
the small intestine and unless stated otherwise, we refer hence-
forth to this tissue, in particular the ileum. Moreover, we restrict
our discussion to the steady-state gut, which is probably in a
constant state of ‘‘primed homeostasis,’’ due to ongoing expo-
sure to microbial stimuli. Finally, intestinal DCs were originally
merely defined as CD11c+ cells and with time subfractionated
into intestinal macrophages (now best defined as CD11c+CD64+
cells) and DC subsets. This fact often prevents definitive conclu-
sions concerning subset-specific functions in particular from
earlier pioneering studies.
The generation of intestinal CD103+CD11b cDCs depends
on BATF3, Id2, and IRF8 and these cells thus represent the gut
equivalent of splenic CD8a+ cDCs.
BATF3-deficient mice display normal populations of Foxp3+
Treg cells in lamina propria and MLNs. Moreover, their CD4+
and CD8+ T cells in the lamina propria and LNs show normal
expression of the gut-homing receptors a4b7 integrin and
CCR9 (Edelson et al., 2010). Thus, the ability to induce Treg cells
(Coombes et al., 2007; Sun et al., 2007) and imprint a homing
signature (Johansson-Lindbom et al., 2005) that has been
reported for intestinal DCs seems to be redundant among thesecells. So far, therefore, no unique functions have been assigned
to CD103+CD11b cDCs, although it could be speculated that
the latter might be associated with their cross-presentation
potential. Although the uptake of infected apoptotic epithelial
cells was shown to affect Th17-cell-mediated immunity (Torchin-
sky et al., 2009), so far no direct link to the CD103+CD11b cDC
subset has been established for this process.
Paradoxically, in the gut it is the ‘‘CD103+CD11b+ cDC’’
population, which is functionally better defined, despite the
fact that it is heterogeneous (Schlitzer et al., 2013; Schreiber
et al., 2013). Intestinal CD103+CD11b+ cDCs were subfractio-
nated via the surface markers CD24 and CD64, revealing their
composition of bona fide Flt3-dependent CD24+CD64 cells
and contaminating CD24CD64+ cells that represent intestinal
macrophages. Development of CD24+CD103+CD11b+ DCs
depends on IRF4 (Schlitzer et al., 2013; Persson et al., 2013)
and most likely also on NOTCH2 (Lewis et al., 2011).
CD103+CD11b+ cDCs prevail in the small intestine over the
colon, coinciding with a descending Th17 cell gradient between
these tissues (Denning et al., 2011). Moreover, these cells have
been shown to express IL6 and TGF-b mRNA, as well as RA-
generating enzymes and efficiently induce the in vitro differ-
entiation of Th17 cells, an activity that was dependent on the
microbiota status of the donor animals (Denning et al., 2011).
Indeed, CD103+CD11b+ DCs are required in vivo for the efficient
generation of Th17 cells as evidenced in mice lacking these cells
either due to a IRF4 and Notch deficiency (Lewis et al., 2011;
Persson et al., 2013; Schlitzer et al., 2013) or as a result of
their conditional ablation (Welty et al., 2013). In contrast,
CD103+CD11b+ DC-derived RA seems dispensable for the
in vivo generation of ‘‘gut tropic’’ T cells, as well as intestinal
FoxP3+ inducible Treg cell development (Persson et al., 2013;
Welty et al., 2013), supporting the earlier notion that these
activities are redundant among intestinal DCs. CD103+CD11b+
DCs seem to have unique direct access to luminal Ags, because
they can translocate into the epithelium, phagocytose patho-
gens, and probably translocate to the MLNs (Farache et al.,
2013). Moreover, ileal CD103+CD11b+ DCs were also reported
to respond to a flagellin-mediated TLR5 trigger with production
of IL-23, thus promoting an antibacterial defense cascade (Kin-
nebrew et al., 2010). Of note, in the colon CD103+CD11b+ cDCs
are exceedingly rare, but might be functionally replaced by a
population of CD103CD11b+ cDCs. Interestingly, when
retrieved from the lymph after lymphadenectomy, these cells
spontaneously induced the differentiation of IFN-g- and IL-17-
producing effector T cells (Cerovic et al., 2013). However,
CD103CD11b+ cDCs remain poorly defined and are currently
difficult to discern from monocyte-derived macrophages and
moDCs.
Lung
The lung, like the intestine, is vulnerable to pathogenic insult
and is constantly exposed to potentially harmful substances.
Pulmonary immune responses pose the challenge to prevent
immunopathology, such as asthma or allergy. Classical studies
have highlighted the abundance of DCs in lung tissue and
their dynamic accumulation upon insult (Holt et al., 1990). DC
ablation from lungs by the CD11c-DTR approach (Jung et al.,
2002) results in delayed T cell responses under various
infectious models like intranasal influenza infection modelImmunity 40, May 15, 2014 ª2014 Elsevier Inc. 649
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applied Ags, lung cDCs migrate to the draining LN in a CCR7-
dependent manner and participate in the induction of T cell toler-
ance over innocuous Ag (Idoyaga et al., 2013).
Two main cDC populations have been identified in the lung:
intraepithelial CD103+CD11b DCs and CD103CD11b+ DCs
in the submucosa of the conducting airways (GeurtsvanKessel
et al., 2008). Development of lung CD103+CD11b cDCs
depends on Id2 and IRF8 (Ginhoux et al., 2009) aligning these
cells with the classical CD8 and CD103 DC lineage. Accordingly,
lung CD103+CD11b cDCs are specialized in cross-presenta-
tion of antigens to CD8+ T cells (del Rio et al., 2007). After influ-
enza virus infection, migratory CD103+ DCs can efficiently
induce CD8+ T effector cells in a CD24-dependent manner
(Kim et al., 2014). Furthermore, CD103+ cDCs express receptors
for apoptotic bodies along with the machinery to cross-present
ingested dead cells (Desch et al., 2011). Interestingly, lung
CD103+CD11b cDCs can penetrate the epithelial cell layer to
gain direct access to the airway lumen without disrupting the
barrier function (Guilliams et al., 2013). These structures, which
are reminiscent of trans-epithelial dendrites reported for intesti-
nal CX3CR1
hi macrophages (Niess et al., 2005), may provide
access to pulmonary Ags. Notably, and in contrast to the skin,
lung CD103+CD11b cDCs and not CD11b+ cDCs prominently
express RALDH after Ag inhalation and seem thereby to facilitate
de novo Treg cell induction (Khare et al., 2013). Of note, it was
also reported that lung CD103+CD11b cDCs might have a
uniquely extended life span as compared to their CD103+
cDCs equivalent in other tissues (Ginhoux et al., 2009).
Lung CD103CD11b+ cDCs remain more enigmatic. As
opposed to skin, LN, or spleen, these cells are in the lung
outnumbered by the cross-presenting CD103+ cDCs (Ginhoux
et al., 2009). Earlier studies suggested that lung CD11b+ cDCs
are potent producers of chemo- and cytokines under physio-
logical as well as under allergic inflammation (Beaty et al.,
2007), although in this study contaminating moDCs had not
been excluded. More recently, CD11b+ cDCs, further defined
as being CD24+, were shown to be dependent on IRF4 (Schlitzer
et al., 2013). CD11b+CD24+ cDCs were found to direct a Th17
cell response to Aspergillus fumigatus challenge, possibly
due to their production of IL-23 (Schlitzer et al., 2013).
CD11b+CD64 cDCs were also reported to efficiently induce
Th2 cell immunity in house dust mite-specific T cells (Plantinga
et al., 2013). In contrast to migratory CD103+ DCs, pulmonary
CD11b+ DCs were shown to trigger after influenza infection the
activation of CTLs that remain in the draining LN and display a
phenotype reminiscent of T memory rather than T effector cells
(Kim et al., 2014). In summary, these data suggest a labor
division among lung cDCs, in that CD103+ cDCs might be
specialized in triggering CTL immunity after viral infections
and the induction of immunological tolerance, whereas
CD11b+ cDCs might efficiently initiate CD4+ T cell responses
and T cell memory.
Concluding Remarks
The recent years have seen major advances in our understand-
ing of the classical DC compartment, starting with the definition
of cDC ontogeny and thereby the firm establishment of these
cells as a separate lineage distinct from monocytes and tissue-650 Immunity 40, May 15, 2014 ª2014 Elsevier Inc.resident macrophages. Moreover, in the mouse there is now
solid evidence for the existence of defined DC subsets, the
XCR1+ (CD8a+ and CD103+) cDCs and CD11b+ cDCs, that
display functional specialization. However, critical gaps remain.
Of note, progress is somewhat impeded by certain ‘‘ghosts in the
DC closet.’’ The popular distinction between ‘‘immature’’ and
‘‘mature’’ DCs, a scheme that originally emerged from in vitro
cultures, implies that the former cells are functionally incompe-
tent; however, DCs can clearly contribute distinct critical func-
tions as they pass through their different activation states.
Another issue is that the DC field is dominated by surface
marker-based definitions. CD103, for instance, is used as a
direct marker for the cDC subset but its expression is regulated
by Csf2 (Zhan et al., 2011). Lack of CD8a+CD103+ cDCs in Csf2-
deficient mice has hence been interpreted as evidence for a crit-
ical role of this factor in CD8a+ and CD103+ cDC development
(Bogunovic et al., 2009; King et al., 2010; Greter et al., 2012) or
simple loss of CD103 expression (Edelson et al., 2011). Emerging
unbiased approaches to the study of cDCs, including massive
parallel single-cell RNA-seq (MARS-seq) (Jaitin et al., 2014),
might help resolve these issue and provide a new definition of
functional entities within the cDC compartment. Another impor-
tant outstanding issue is whether moDCs contribute merely
quantitatively or also qualitatively to the functions provided by
the cDC compartment and immunity. Finally, to get us closer
to fulfill Ralph Steinman’s vision of the rational exploitation of
the powerful DC activities for vaccination and anticancer ther-
apy, we require a better alignment of the murine cDC subpopu-
lations with the less-well-characterized human DCs. Taken
together, the future of DCs is bright but there’s much left to do
and to cite Ralph Steinman’s enthusiastic concluding remark
at the annual DC meetings, ‘‘Let’s get back to work.’’ACKNOWLEDGMENTS
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